ORKAOruka Therapeutics, Inc.
$82.17+428% 1Y
$82.17
$15.0552 weeks$113.05
ORKA in its own filings
ORKA's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
604
Events found in the filings · across 1,528 filings · the record starts in 1997
- Hard flags
- 1
Hard flags
- Most recent filing
- Aug 24, 2026
Most recent filing · Form 8-K
- Record starts
- Aug 22, 1997
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filinga quarter after the last one
- expected around Nov 9, 2026
- Change in certifying accountant3 occurrences
- 2024-09-05
- Delisting notice / listing-rule failure14 occurrences
- 2019-04-22
- SEC comment-letter activity36 occurrences
- 2026-04-08
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 24, 2026On July 22, 2026, Oruka Therapeutics, Inc. entered into a letter agreement with Todd Edwards pursuant to which Mr. Edwards commenced employment as Chief Commercial Officer on August 24, 2026.Director or officer change · Form 8-K
- Aug 10, 2026Oruka Therapeutics Reports Second Quarter 2026.Earnings release · press release
- Jun 1, 2026On May 29, 2026, Oruka Therapeutics, Inc. (the “Company”) entered into the First Amendment to IL-23 License Agreement (the “Amendment”), amending the IL-23 License Agreement dated as of December 17, 2024 (the “License Agreement”), by and between the Company and Paragon Therapeutics, Inc. (“Paragon”)Other event · Form 8-K
- Apr 30, 2026On April 28, 2026, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC, Goldman Sachs & Co. LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the several underwriters named in Schedule …Earnings release · Form 8-K
- Apr 27, 2026On April 27, 2026, Oruka announced results from its Phase 2a EVERLAST-A clinical trial of ORKA-001 in patients with moderate-to-severe PsO. EVERLAST-A Phase 2a Key 16-Week Results The Phase 2a EVERLAST-A clinical trial is a randomized, double-blind, placebo-controlled study evaluating ORKA-001 in patients with …Regulation FD disclosure · Form 8-K
- Dec 11, 2025Resignation of Director On December 11, 2025, Cameron Turtle resigned as a member of the Board of Directors (the “Board”) of Oruka Therapeutics, Inc. (“Oruka” or the “Company”)Director or officer change · Form 8-K
- Sep 22, 2025On September 17, 2025, Oruka Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”)Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks